Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

DOP36: Gut microbial variations in patients with quiescent Crohns disease predict subsequent disease flareECCO'19 Copenhagen
Year: 2019
Authors: Yael Haberman
Microbiota, Crohn’s disease, Calprotectin and other faecal biomarkers, CRP and other serum biomarkers, Prognosis, Microbiota
Files: 1
DOP37: Vedolizumab-induced endoscopic remission in anti-TNF exposed and anti-TNF naïve IBD patients: a large single centre experienceECCO'19 Copenhagen
Year: 2019
Authors: Bram Verstockt
colonoscopy, Mucosal healing, Vedolizumab, Mucosal healing, Real world data, Mucosal healing
Files: 1
DOP38: A vedolizumab specific four-gene colonic signature accurately predicting future endoscopic remission in patients with inflammatory bowel diseaseECCO'19 Copenhagen
Year: 2019
Authors: Bram Verstockt
Mucosal healing, Prognosis, Anti-TNF agents, Vedolizumab
Files: 1
DOP39: Safety of Combination Biologic and Anti-Rejection Therapy Post-Liver Transplantation in Patients with Inflammatory Bowel Disease: London Ontario ExperienceECCO'19 Copenhagen
Year: 2019
Authors: Christopher Ma
Adalimumab, Anti-TNF agents, Golimumab, Infliximab, Ustekinumab, Vedolizumab, Sclerosing Cholangitis, IBD-associated cancer, Clostridium difficile, Colorectal cancer, CMV, IBD and malignancy, Mortality, Real world data, Patient reported outcomes
Files: 1
DOP40: Effectiveness and safety of reference infliximab and biosimilar in Crohn’s disease: a French equivalence studyECCO'19 Copenhagen
Year: 2019
Authors: Antoine Meyer
Anti-TNF agents, Biosimilars, Real world data
Files: 1
DOP41: Efficacy and safety of open-label treatment with tofacitinib 10 mg twice daily in patients with ulcerative colitis with clinical response, but not remission, after 52 weeks of maintenance therapy: Data from the OCTAVE studiesECCO'19 Copenhagen
Year: 2019
Authors: Russell D Cohen
Tofacitinib, JAK inhibitors, Ulcerative colitis
Files: 1
DOP42: Dietary Therapies Induce Rapid Response and Remission in Active Paediatric Crohn’s DiseaseECCO'19 Copenhagen
Year: 2019
Authors: Rotem Sigall-Boneh
CRP and other serum biomarkers, Disease activity Indices, Dietary therapy, Exclusive enteral nutrition, Paediatric, Disease activity indices
Files: 1
DOP43: Long-term efficacy of tofacitinib in patients who received extended induction therapy: Results of the OCTAVE Open study for tofacitinib delayed respondersECCO'19 Copenhagen
Year: 2019
Authors: Milan Lukas
Tofacitinib
Files: 1
DOP44: Efficacy and safety of tacrolimus in ulcerative colitis: a nationwide, multicentric study from GETECCUECCO'19 Copenhagen
Year: 2019
Authors: Iago Rodriguez-Lago
Ulcerative colitis, Tacrolimus, Real world data
Files: 1
DOP45: Adequate infliximab exposure during the induction phase is associated with early complete fistula response in patients with fistulizing Crohn’s disease: a post-hoc analysis of the ACCENT-2 trialECCO'19 Copenhagen
Year: 2019
Authors: Niels Vande Casteele
Anti TNF drug levels, Therapeutic drug monitoring, Anti-TNF agents, Infliximab, Pharmacokinetics
Files: 1
DOP46: Extended induction treatment with mirikizumab in patients with moderately-to-severely active ulcerative colitis: results from a phase 2 trialECCO'19 Copenhagen
Year: 2019
Authors: William J. Sandborn
Ulcerative colitis, Commercial
Files: 1
DOP47: Sustained remission in patients with moderate to severe ulcerative colitis: Results from the phase 3 UNIFI maintenance studyECCO'19 Copenhagen
Year: 2019
Authors: Laurent Peyrin-Biroulet
Ulcerative colitis, Mucosal healing, Ustekinumab, Patient reported outcomes, Disease activity indices, Mucosal healing
Files: 1
DOP48: Amiselimod, a selective S1P receptor modulator in Crohn's disease patients: a proof of concept studyECCO'19 Copenhagen
Year: 2019
Authors: Geert D'Haens
S1P agonist
Files: 1
DOP49: Efficacy of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in ulcerative colitis: results from the open-label extension study TURANDOT IIECCO'19 Copenhagen
Year: 2019
Authors: Walter Reinisch
Ulcerative colitis
Files: 1
DOP51: Biomarker and pharmacokinetic data from the TURANDOT II open-label extension study of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in patients with ulcerative colitisECCO'19 Copenhagen
Year: 2019
Authors: Walter Reinisch
Ulcerative colitis, Calprotectin and other faecal biomarkers, CRP and other serum biomarkers
Files: 1
DOP52: Reduction in inflammatory biomarkers in a phase 2 study of mirikizumab in patients with moderately-to-severely active ulcerative colitisECCO'19 Copenhagen
Year: 2019
Authors: William J. Sandborn
Ulcerative colitis, Commercial
Files: 1
DOP53: Clinical, Endoscopic, Histologic and Biomarker Activity Following Treatment with the Gut-Selective, pan-JAK Inhibitor TD-1473 in Moderately-to-Severely Active Ulcerative ColitisECCO'19 Copenhagen
Year: 2019
Authors: Julián Panés
JAK inhibitors
Files: 1
DOP54: Efficacy and safety of ustekinumab through week 16 in patients with moderate to severe ulcerative colitis randomised to ustekinumab: Results from the UNIFI induction trialECCO'19 Copenhagen
Year: 2019
Authors: Silvio Danese
Ulcerative colitis, Ustekinumab
Files: 1
DOP55: ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases using whole-exome sequencingECCO'19 Copenhagen
Year: 2019
Authors: Eun Suk Jung
Anti-TNF agents, Infliximab, Pharmacogenetics
Files: 1
DOP57: Monitoring response to anti-TNF therapy in ulcerative colitis patients by gastrointestinal ultrasound: sub-analysis from TRUST UCECCO'19 Copenhagen
Year: 2019
Authors: Christian Maaser
Ulcerative colitis, Calprotectin and other faecal biomarkers, CRP and other serum biomarkers, Mucosal healing, Ultrasound, Adalimumab, Anti-TNF agents, Golimumab, Infliximab, Real world data, Mucosal healing
Files: 1